Primary entity: MOTS-cClass: Mitochondrial-encoded research peptide (not FDA-approved)Cluster: Specialty
MOTS-c is a short peptide encoded in mitochondrial DNA (within the 12S rRNA locus) that has been studied as a metabolic signaling molecule in cell and animal research. It is not an FDA-approved drug. Online “exercise mimetic / longevity peptide” marketing runs ahead of completed human outcome evidence suitable for medical claims.
Encoding in mtDNA and metabolic phenotypes in rodents are scientifically interesting. They do not create an approved therapy or justify gray-market self-experimentation protocols.
Not FDA-approved. Any clinical-trial registry activity should be verified on ClinicalTrials.gov by official title/NCT. RUO vials are not clinical supply.
Covered by HHS's Oct 28, 2026 interim enforcement-discretion policy for licensed-pharmacy (503A) compounding: acetate form; subcutaneous or intramuscular; single ingredient; valid prescription; conditions apply. Not FDA-approved, not on the final bulks list, and not a green light for RUO vials. Interim and revocable. See the compounding status guide.
Key takeaways
- MOTS-c is a mitochondrial-encoded research peptide — unusual origin story vs nuclear-encoded peptides.
- Not FDA-approved; metabolic/exercise-adjacent marketing ≠ label.
- Evidence is strongest in cell/animal work; human outcome maturity remains limited.
- No dosage chart on this site.
Questions this page answers
Next questions we answer on this page (curiosity / AI-gap map):
- What is MOTS-c?
- Also known as
- Classification
- What it is NOT
- Mechanism literacy
- Evidence ladder
- What’s been studied
- Safety literacy
- Regulatory status
- Why no dosages
- Related compounds
- Who for / not for
Who is this profile for — and who is it not for?
For: readers who want mitochondrial-peptide literacy without longevity hype.
Not for: anyone seeking buy links, “MOTS-c cycles,” or medical advice.
What is MOTS-c?
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a peptide expressed from the mitochondrial genome and studied for roles in metabolic regulation, stress adaptation, and exercise-related phenotypes in research models. That biology explains specialty-cluster demand next to metabolic small molecules — it does not make MOTS-c an approved weight-loss or performance drug.
See also What are peptides?.
| Origin | Mitochondrial DNA–encoded peptide |
|---|---|
| Typical research framing | Metabolic / exercise-adjacent signaling |
| U.S. approval | Not FDA-approved |
| Evidence center of gravity | Cell + animal; human limited |
| DIY/RUO | Not a substitute for approved care |
Also known as
- MOTS-c / MOTSc / MOTS c — common spellings.
- Mitochondrial 12S rRNA ORF peptide — descriptive expansion.
- Folk: “mito peptide,” “exercise peptide” — marketing shorthand, not approval.
Origin story ≠ clinical proof. Longevity marketing is a curiosity gap we close with evidence-ladder language.
How is MOTS-c classified?
Investigational / research peptide in the specialty cluster — unapproved for medical marketing claims in the U.S. Distinct from FDA-approved metabolic peptide drugs (e.g., GLP-1 agonists).
What is MOTS-c not?
| MOTS-c is not… | Why that matters |
|---|---|
| FDA-approved drug | No U.S. approval |
| Same as GLP-1 medicines | Different biology and evidence bar |
| Proven longevity injectable | Hype gap |
| Something we dose or source | Refusal |
How is MOTS-c thought to work?
Research models link MOTS-c to metabolic homeostasis and stress-response signaling, including interactions with pathways relevant to insulin sensitivity and exercise adaptation in animals. Treat mechanism summaries as literacy — not outcome guarantees for humans buying RUO vials.
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Cell | Metabolic signaling / mechanistic studies | Cell |
| Animal | Diet, exercise, metabolic phenotype models | Animal |
| Human | Limited; verify any biomarker or interventional studies individually | Human Thin — |
| Approved label | None | None |
What has MOTS-c been studied for?
Published interest includes metabolic disease models, exercise physiology adjacency, and cellular stress adaptation. Studied ≠ approved therapy.
What safety topics come up?
No approved U.S. prescribing information. Human long-term safety as a consumer “research peptide” is not established like labeled drugs. Product quality of gray-market vials is a separate risk. Not medical advice.
What is MOTS-c's regulatory status?
- U.S.: Not FDA-approved.
- Trials: Confirm any interventional studies on ClinicalTrials.gov.
- RUO market: Research labeling ≠ clinical quality.
Why doesn't this page include a dosage chart?
Unapproved; human outcome evidence limited; “MOTS-c dosage” queries seek protocols. Literacy refusal.
Related lab literacy
Concept-level reconstitution literacy only via how-to hub — not a MOTS-c protocol.
Related compounds and comparisons
- SS-31 (elamipretide) — another mitochondria-associated research peptide (different entity; not interchangeable).
- 5-Amino-1MQ — NNMT small molecule (not a peptide; metabolic adjacency).
- BAM15 — mitochondrial uncoupler small molecule (not a peptide).
- ATX-304 — AMPK-pathway investigational small molecule.
- Tirzepatide — approved metabolic peptide drug (do not equate).
Frequently asked questions
Is MOTS-c a mitochondrial peptide?
Yes in the research sense: it is encoded in mitochondrial DNA. That is a biology fact, not an approval.
Is MOTS-c FDA approved?
No.
Is MOTS-c an exercise mimetic drug?
It is studied in exercise/metabolic research models. It is not an FDA-approved exercise-mimetic medicine.
How does it compare to GLP-1 drugs?
Different class and evidence bar. Approved GLP-1/GIP medicines have labels; MOTS-c does not.
Why no dosage chart?
Unapproved status and YMYL policy.
MOTS-c is not FDA-approved. Educational only. Disclaimer.
Sources
- Primary — preclinical Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009. PMID: 25738459. Foundational discovery/mechanism paper (preclinical).
- Primary — preclinical Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7. doi:10.1016/j.cmet.2018.06.008. PMID: 29983246.
- Registry ClinicalTrials.gov search for MOTS-c. Accessed November 10, 2026.
- Written by
- Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
- Published · Updated
- Oct 6, 2026 · Nov 10, 2026 · Labels, trial citations, and WADA list wording checked Nov 10, 2026 · How we source & update
Educational disclaimer: Educational only. No dosing or buy links. We don’t sell peptides. Read our full disclaimers.